The SA Health Products Regulatory Authority (SAHPRA) has approved Aspen Pharmacare’s diabetes drug Mounjaro (tirzepatide) to be used as a chronic weight-management treatment. – Business Day (13 October 2025)
The treatment is available as the Mounjaro KwikPen, a pre-filled injection device that patients can use at home.
Recent research from the Bhekisisa Centre for Health Journalism found that, although diabetes is the leading cause of death among SA women, obesity is a dangerously prevalent co-morbidity: 68% of women and 31% of men are overweight or obese.